Get the Daily Brief
Latest Biotech News
Lilly buys Adverum to fast‑track one‑time gene therapy for wet AMD
Eli Lilly agreed to acquire Adverum in a deal focused on ixoberogene soroparvovec (ixo‑vec), a Phase 3 gene therapy candidate for wet age‑related macular degeneration designed as a one‑time...
BridgeBio racks up rare‑disease wins: encaleret Phase 3 success and FDA path eyed
BridgeBio reported Phase 3 success for encaleret in autosomal dominant hypocalcemia type 1 (ADH1), meeting primary and key secondary endpoints with 76% of treated patients achieving serum and...
AI drug discovery deals accelerate: phenomaps and multispecific antibody partnerships
Recursion delivered a genome‑scale microglia phenomap to Roche/Genentech as part of their multi‑year collaboration, triggering a $30 million milestone payment and providing a 46‑million image...
10x Genomics launches next‑gen Flex: massive single‑cell scale meets cost cuts
10x Genomics unveiled the next generation of its Chromium Flex assay, featuring plate‑based, automation‑compatible multiplexing that scales to 384 samples and up to 100 million cells per week....
GSK buys ADC rights, ADC developers present data: pharma doubles down on targeted payloads
GSK struck a headline ADC licensing deal with Syndivia for a preclinical ADC targeting metastatic castration‑resistant prostate cancer, agreeing to pay up to €357 million in upfront and milestone...
FDA halts Intellia’s CRISPR phase-3 trials — liver safety probe
The FDA placed clinical holds on two late-stage Intellia Therapeutics trials testing its in vivo CRISPR therapy for transthyretin amyloidosis (ATTR) after a patient developed serious liver injury....
Novo storms Metsera auction — Pfizer fights back
Novo Nordisk submitted an unsolicited, superior proposal to buy obesity biotech Metsera, challenging Pfizer’s previously announced acquisition and igniting a cross‑border bidding war. Novo’s offer...
GSK takes Syndivia ADC program — $357m upfront for prostate target
GlaxoSmithKline agreed to acquire exclusive rights to Syndivia’s preclinical antibody‑drug conjugate (ADC) targeting metastatic castration‑resistant prostate cancer (mCRPC) in a deal that includes...
BridgeBio posts late‑stage wins — rare disease filings next
BridgeBio announced positive phase 3 results for encaleret in autosomal dominant hypocalcemia type 1 (ADH1), meeting primary and key secondary endpoints with 76% of treated patients achieving...
Lilly posts blowout quarter — builds $1.2B plant for oral GLP‑1
Eli Lilly reported third‑quarter revenue that materially exceeded Street expectations and raised its full‑year outlook, driven by blockbuster performance from its diabetes and weight‑loss...
Thermo Fisher to buy Clario — $8.9B cash deal for trial data software
Thermo Fisher Scientific agreed to acquire Clario, a clinical‑trial data and software company, for approximately $8.9 billion in cash plus earn‑outs, aiming to expand its presence in trial...
FDA proposes cutting clinical‑trial bar for biosimilars — faster copycats
The FDA published draft guidance proposing to eliminate routine comparative clinical efficacy studies for many biosimilar applications, a move intended to shorten development timelines and lower...
Recursion delivers microglia phenomap to Roche — $30m milestone hit
Recursion disclosed delivery of a whole‑genome microglia phenomap to Roche/Genentech under their multi‑year AI discovery collaboration, triggering a $30 million milestone payment. The dataset...
Sensei winds down lead program — halts trial, readies layoffs
Sensei Biotherapeutics said it will stop development of its only clinical‑stage asset, solnerstotug, wind down the ongoing Phase 1/2 study and implement workforce reductions to preserve cash. The...
Takeda abandons alpha‑synuclein program after phase‑2 miss
Takeda said it will discontinue development of TAK‑341 (MEDI1341), an alpha‑synuclein antibody it was co‑developing with AstraZeneca, after a global Phase 2 study in multiple system atrophy (MSA)...
FDA halts Intellia gene-editing trials: clinical hold after liver injury
The U.S. Food and Drug Administration placed a clinical hold on Intellia Therapeutics’ two late‑stage trials of its experimental gene‑editing therapy following a serious liver injury in a treated...
Thermo Fisher to buy Clario — $8.9–$9.4B takeover targets trial data stack
Thermo Fisher Scientific agreed to acquire Clario, a clinical‑trial data‑solutions provider, in a cash deal valued at roughly $8.9–$9.4 billion, according to multiple reports. The move gives...
Roche pays into China bispecific — $1B+ pact for respiratory candidate
Roche struck a licensing agreement with Jiangsu‑based Qyuns Therapeutics securing global rights to QX‑031N, a clinical‑stage bispecific antibody aimed at respiratory disease, in a deal that could...
FDA pivots on biosimilars: draft guidance to cut clinical requirements
The U.S. Food and Drug Administration proposed new draft guidance to streamline biosimilar development, indicating the agency will no longer routinely require comparative clinical efficacy trials...
BridgeBio posts Phase III win — encaleret meets endpoints in genetic hypoparathyroidism
BridgeBio reported positive top‑line results from a global Phase III trial of encaleret for autosomal dominant hypocalcemia type 1 (ADH1), with 76% of treated patients reaching predefined serum...